Main Article Content
Objective: When metastasis develops in some breast cancer patients, hormone receptors (HR) and Human Epidermal Growth Factor-2 (Her-2) status can change and the tumor alters its character. We tried to determine the rate of these changes in tumor biology in 110 patients that we followed in our clinic and performed the change of the biopsy from the metastatic site (re-bx). We aimed to determine the biological changes of tumors and, contribute to the literature by examining the relationship of these changes with the adjuvant endocrine treatments (ET) or chemotherapy type (CT).
Material and Methods: We included 110 metastatic breast cancer patients in our study. These patients had previously completed their local treatments followed by CT, and those with positive HR completed ET. After the first metastasis developed in the patients, we performed metastasectomy or biopsy from the metastatic site.
Results: The median ki-67 value was 25% at the time of primary diagnosis and 30% in re-bx. 20.9% of patients estrogen receptor (ER), 31.8% of patients progesterone receptor (PR) and 26.3% of patients Her-2 changed when metastasis developed.
Conclusions: We found that the metastatic tumor has more aggressive properties than the primary tumor. Adjuvant chemotherapy and endocrine treatments or the location of metastasis did not make a significant difference in tumor biology.
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
2. Kesson EM, Allardice GM, George WD, et al. Effects of multidisciplinary team working on breast cancer survival: retrospective, comparative, interventional cohort study of 13 722 women BMJ. 2012 Apr 26;344:e2718.
3. F. Cardoso , A. Costa , L. Norton et al. First international consensus guidelines for advanced breast cancer (ABC 1). Breast 2012;21:242–252
4. Amir E, Clemons M. Should a biopsy be recommended to confirm metastatic disease in women with breast cancer Lancet Oncol 2009;10:933–935
5. Özmen Vahit. Journal of Breast Health . 2014;10:98-105
6. Cardoso F, Spence D, Mertz S et al. Global analysis of advanced/metastatic breast cancer: Decade report (2005-2015). Breast 2018 Jun 19;39:131-138
7. Lu J, Steeg PS, Price JE et al. Breast cancer metastasis: challenges and opportunities. Cancer Research 2009 Jun;15:69(12):4951-3
8. J Ferlay , M Colombet , I Soerjomataram et al. Estimating the global cancer incidence and mortality in 2018: Globocan sources and methods. Int J Cancer 2019 Apr 15;144(8):1941-1953
9. Ongaro E, Gerratana L, Cinausero M et al. Comparison of primary breast cancer and paired metastases: biomarkers discordance influence on outcome and therapy. Future Oncol 2018 Apr;14: 849-859
10. Kulka J, Székely B, Lukács LV et al. Comparison of predictive immunohistochemical marker expression of primary breast cancer and paired distant metastasis using surgical material: A practice-based study. J Histochem Cytochem 2016 Apr; 64(4): 256–267.
11. Liedtke C, Broglio K, Moulder S et al. Prognostic impact of discordance between triple receptor measurements in primary and recurrent breast cancer. Ann Oncology 2009 Dec;20(12):1953-8
12. Curtit E, Nerich V, Mansi L et al. Discordances in estrogen receptor status, progesterone receptor status, and HER2 status between primary breast cancer and metastasis. Oncologist 2013 Jun;18(6):667-74
13. Shachar SS, Mashiach T, Fried G et al. Biopsy of breast cancer metastases: patient characteristics and survival. BMC Cancer 2017 Jan;7(1):7-17
14. Tobin NP, Harrell JC, Lövrot J et al. Molecular subtype and tumor characteristics of breast cancer metastases as assessed by gene expression significantly influence patient post-relapse survival. Ann Oncol 2015;26: 81-88
15. Aurilio G, Disalvatore D, Pruneri G et al. A meta-analysis of oestrogen receptor, progesterone receptor and human epidermal growth factor receptor 2 discordance between primary breast cancer and metastases. Eur J Cancer 2014;50: 277-289
16. Bogina G, Bortesi L, Marconi M et al. Comparison of hormonal receptor and HER-2 status between breast primary tumours and relapsing tumours: clinical implications of progesterone receptor loss. Virchows Archiv 2011;459: 1-10
17. Constanze V, Wolfram M, Bernd M et al.The Role of Previous Therapies and Sites of Metastasis as Influencing Factors on Discordance of ER, PR and HER2 Status Between Primary and Metastasized Breast Cancer. Anti Cancer Research 2019;39: 2647-2659